750 completed, 165 terminated, 81 recruiting, 73 active not recruiting. 402 Phase 2, 274 Phase 3, 225 Phase 1, 147 Phase 4, 95 Not applicable.
Follow Gilead Sciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer TUB-040 - NSCLC, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Gilead Sciences | 80 | 2026-11-01 | 2026-09-16 |
| Tenofovir Exposures in Advanced Kidney Disease Study Plasma sampling for tenofovir and emtricitabine, Descovy - Tenofovir, Tenofovir Alafenamide Fumarate | Not yet recruiting | King's College Hospital NHS Trust | 50 | 2026-11-01 | 2026-09-10 | |
| Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill - Talaromycosis | Phase 3 | Not yet recruiting | Duke University | 428 | 2026-11-01 | 2026-09-21 |
| Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy TUB-040 - Dose escalation, TUB-040 - RP2D - Uterine Endometrial Cancer | Phase 1 / Phase 2 | Not yet recruiting | Gilead Sciences | 100 | 2026-10-01 | 2026-08-05 |
| Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis Seladelpar, PTM Seladelpar, Cilofexor Dose B - Primary Biliary Cholangitis | Phase 2 | Not yet recruiting | Gilead Sciences | 132 | 2026-10-01 | 2026-09-25 |
| Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) 12 mg of nebulised 99mTc-liposomal amphotericin B, 24 mg of nebulised 99mTc-liposomal amphotericin B, SPECT/CT scan - Chronic Pulmonary Aspergillosis | Phase 1 | Not yet recruiting | Radboud University Medical Center | 18 | 2026-10-01 | 2026-08-18 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels B/F/TAF, GS-3242, Lenacapavir - HIV-1 Infection | Phase 2 | Not yet recruiting | Gilead Sciences | 125 | 2026-09-01 | 2026-09-25 |
| SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates scalp cooling, photographs via the Belle.AI app, Antibody-Drug Conjugates - Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate | Phase 2 | Not yet recruiting | Jules Bordet Institute | 102 | 2026-09-01 | 2026-08-19 |
| Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package - HIV Infection, Sexually Transmitted Infection | Phase 3 | Not yet recruiting | HIV Prevention Trials Network | 400 | 2026-09-01 | 2026-06-22 |
| NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy - Breast Cancer, Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Women's Cancer Study Group GmbH | 765 | 2026-08-30 | 2026-08-05 |
| Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care Research Assistant Support - Shared Decision-Making, Quality of Life | Not applicable | Recruiting | Stanford University | 138 | 2026-08-26 | 2026-08-27 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Denikitug, Nivolumab, Ramucirumab - HER2-negative, Gastroesophageal Junction | Phase 2 | Recruiting | Gilead Sciences | 120 | 2026-08-07 | 2026-09-21 |
| Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet - HIV-1-infection | Phase 2 / Phase 3 | Recruiting | Gilead Sciences | 700 | 2026-07-29 | 2026-10-13 |
| Study of GS-0415 and How It Works in People With HIV GS-0415, GS-0415 Placebo - HIV -1 Infection | Phase 1 | Recruiting | Gilead Sciences | 112 | 2026-07-22 | 2026-09-23 |
| A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors GS-1206 - Solid Tumor | Phase 1 | Recruiting | Gilead Sciences | 302 | 2026-07-17 | 2026-09-08 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV Infections | Phase 3 | Recruiting | Gilead Sciences | 590 | 2026-07-14 | 2026-08-14 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV-1-infection | Phase 3 | Recruiting | Gilead Sciences | 590 | 2026-07-14 | 2026-07-30 |
| Leveraging Chatbot to Improve PrEP in the Southern United States A chatbot designed to promote PrEP awareness and uptake for Black MSM, General educational messages - HIV Prevention, PrEP Awareness | Not applicable | Recruiting | Yale University | 145 | 2026-07-13 | 2026-09-23 |
Showing 20 of 1205. Sign in to see all of them.
Hepatitis C (153) · HIV Infections (140) · Acquired Immunodeficiency Syndrome (91) · Hepatitis C, Chronic (55) · Hepatitis B (49) · Hepatitis B, Chronic (46) · Leukemia, Lymphocytic, Chronic, B-Cell (44) · Breast Neoplasms (37) · Hepatitis (30) · Cystic Fibrosis (26) · Lymphoma, Non-Hodgkin (26) · COVID-19 (24) · Triple Negative Breast Neoplasms (22) · Fibrosis (21) · Hypertension, Pulmonary (20)
Tenofovir (103) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (79) · sacituzumab govitecan (70) · Emtricitabine (59) · Sofosbuvir (57) · Ranolazine (48) · bictegravir, emtricitabine, tenofovir alafenamide, drug combination (48) · ledipasvir, sofosbuvir drug combination (46) · sofosbuvir-velpatasvir drug combination (45) · idelalisib (42) · Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (40) · Ribavirin (34) · tenofovir alafenamide (29) · emtricitabine tenofovir alafenamide (27) · Ritonavir (26)
United States (805) · France (222) · United Kingdom (221) · Canada (214) · Germany (198) · Spain (192) · Australia (167) · Italy (164) · Belgium (118) · Puerto Rico (112) · Poland (96) · New Zealand (94) · South Korea (89) · Netherlands (84) · Austria (73)
William Wegener, MD, PhD (10) · John Flaherty, PharmD (8) · Robert H. Hyland, DPhil (6) · Bittoo Kanwar, MD (5) · John McNally, PhD (5) · Patrick Yue, MD (5) · Kathryn Kersey, MSc (4) · Mark Bresnik, MD (4) · Marshall Fordyce, MD (3) · Peter Hodsman, MD (3) · Robert H Hyland, DPhil (3) · Shampa De-Oertel, PhD (3)
PMID 35728046, PMID 36205910, PMID 37747626, PMID 25040192, PMID 25583164, PMID 27847279, PMID 33307033, PMID 36695483, PMID 36750244, PMID 37771546, PMID 19052126, PMID 25987775, PMID 27553375, PMID 29956087, PMID 30932951, PMID 34980223, PMID 36740893, PMID 36912172, PMID 38057656, PMID 38985247, PMID 40657894, PMID 19451441, PMID 20955704, PMID 21816833, PMID 23234725, PMID 23364953, PMID 23607593, PMID 23607594, PMID 23939953, PMID 24209977, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24908550, PMID 25154045, PMID 25179493, PMID 25277773, PMID 25532501, PMID 25788199, PMID 25890673, PMID 26472751, PMID 26542378, PMID 26575258, PMID 26743093, PMID 26829661, PMID 26892863, PMID 27248633, PMID 27658343, PMID 27742226, PMID 28076335
2015 (40), 2016 (39), 2014 (32), 2023 (18), 2019 (15), 2017 (14), 2018 (8), 2025 (8), 2008 (3), 2009 (3), R01MH110057 (3), 2004 (2), 2005 (2), U01AI068636 (2), U10CA031946 (2)